PMGC Holdings (ELAB) Receivables (2022 - 2026)

PMGC Holdings (ELAB) posted Receivables of $428106.0 for Q1 2026, up 74.44% sequentially from $245423.0 in Q4 2025.

PMGC Holdings (ELAB) Receivables (2022 - 2026) Analysis & Trends

PMGC Holdings has reported Receivables for 5 years, with the latest figure at $428106.0 in Q1 2026.

Quarterly Receivables changed N/A year-over-year to $428106.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $428106.0 (changed N/A YoY) and the FY2025 annual result came in at $245423.0, up 4551.69% from the prior year.
Receivables climbed to $428106.0 in Q1 2026 per ELAB's latest filing, from $245423.0 in the prior quarter.
Over five years, Receivables peaked at $8.4 million in Q3 2023 and troughed at $3072.0 in Q4 2023.
A 5-year average of $945938.5 and a median of $41637.5 in 2024 frame the typical range for Receivables.
The sharpest annual moves came in 2024 and 2025: Receivables tumbled 99.67% in 2024, then soared 4551.69% in 2025.
Over 5 years, Receivables stood at $12854.0 in 2022, then tumbled by 76.1% to $3072.0 in 2023, then jumped by 71.74% to $5276.0 in 2024, then jumped by 4551.69% to $245423.0 in 2025, then surged by 74.44% to $428106.0 in 2026.
According to Business Quant data, Receivables over the past three periods registered $428106.0, $245423.0, and $271492.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	1.93 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	912.74 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	215.33 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	1.09 Bn
10	PMGC Holdings	3.01 Mn	-15.78 Mn	385,691.00	421,859.00

Download Data